Navigation Links
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
Date:6/11/2008

Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a

New Report from Decision Resources

WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces closure and healing of fistulas in a greater percentage of patients than Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, would earn a 30 percent patient share in the treatment of Crohn's disease, according to surveyed gastroenterologists.

The new report entitled Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab finds that surveyed gastroenterologists indicated that they would prescribe Centocor/Janssen-Cilag's ustekinumab to 30 percent of their patients with Crohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percent patient share of the U.S. Crohn's disease market in 2012.

The report also finds that UCB's Cimzia will earn Decision Resources' proprietary clinical gold standard ("clinical gold standard") status for the treatment of Crohn's disease by 2011 as interviewed gastroenterologists indicate that Cimzia's efficacy and delivery profiles are superior to those of the current clinical gold standard, Abbott/Eisai's Humira. Although surveyed gastroenterologists indicated that Cimzia has advantages in efficacy and delivery, the therapy may be associated with more minor side effects when compared to Humira.

"Interviewed gastroenterologists report that Cimzia's pegylated formulation may prolong the drug's effect, resulting in a slightly more effective maintenance therapy with a superior maintenance dosing schedule in comparison to Humira," said Kathryn Benton, analyst at Decision Resources. "As a result, we forecast Cimzia to replace Humira as the clinical gold standard because of its incremental advantage in delivery and maintenance of clinical remission."

About the Report

Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
3. Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)
4. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
5. Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
10. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
11. What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned insurance company ... launching a cooperative charity drive with the Tarrant Area Food Bank in the hopes ... and families in need, the Tarrant County Food Bank offers hope and security to ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces ... The print component of “Revolutionizing Cancer Care” is distributed within the February 12 ... Seattle, with a circulation of approximately 250,000 copies and an estimated readership of ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to announce the ... in Norwalk, serves as the host site and directing the camps is PGA Professional ... had successful camps in recent years around Des Moines and are fortunate to have ...
(Date:2/12/2016)... ... 12, 2016 , ... The aging population and longer life ... care. With that, says Patrick Loughney, president of Longtree & Associates, LLC ... term care environments. His company, which offers prep courses and workshops in long ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
Breaking Medicine Technology: